Christopher Posner
CIK 1748265 · PRESIDENT AND CEO · last filed 2025-03-04
Christopher Posner is a PRESIDENT AND CEO who has filed 23 SEC Form 4 insider transactions across 1 company since 2018. The most recent filing shows the insider sold $2.8K of CARA on Mar 4, 2025. Across all open-market trades the lifetime net is −$427.4K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CARA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL
STAMFORD, CT 06902
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Tvardi Therapeutics, Inc. (CARA) Delisted | PRESIDENT AND CEO | 4,370 | $15.96 | $69.7K | -$427.4K | 23 | 2025-03-04 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −583 | -$2.8K | EDGAR |
| 2025-02-06 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −372 | -$1.8K | EDGAR |
| 2024-11-06 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −3,668 | -$1.1K | EDGAR |
| 2024-08-02 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −4,149 | -$1.5K | EDGAR |
| 2024-05-06 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −3,936 | -$3.0K | EDGAR |
| 2024-03-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −5,834 | -$5.2K | EDGAR |
| 2024-02-12 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −35,575 | -$18.9K | EDGAR |
| 2024-02-05 | Tvardi Therapeutics, Inc. (CARA) Delisted | Mixed | +57,519 | -$2.7K | EDGAR |
| 2023-11-03 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −3,796 | -$4.6K | EDGAR |
| 2023-08-04 | Tvardi Therapeutics, Inc. (CARA) Delisted | Sell (S) | −4,307 | -$13.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.